Subscribe to Newsletter
Manufacture Vaccines, Trends & Forecasts, Standards & Regulation, COVID-19

The Pandemic Diaries

Mike Grippo, Senior Vice President, Strategy & Corporate Development at Catalent Pharma Solutions

COVID-19 is one of the greatest humanitarian challenges of our lifetime. I see companies acting with great resolve and resilience, addressing the immediate challenges of COVID-19, and what it represents to their workforce, customers, partners and patients. I see “unsung” heroes – people who persevere and perform in important but less visible jobs – making a significant difference. It makes me proud to be part of Catalent and proud to work in the biopharma industry. My hope is that when we emerge from this crisis, we will reimagine and reinvent. Necessity is the mother of invention. Our industry is trying new things every day. What have we learned that can be applied to the future and perhaps made permanent?  How can we accomplish things faster, more efficiently, and at lower cost? What did we stop doing that is not missed? Perhaps we can apply these learnings to the drug development process. I see a period emerging where governments are going to focus on decreasing the time and cost to get new drugs to market. We are already starting to see great cooperation between our industry and global regulatory bodies around COVID-19 trials. Hopefully, much of this collaboration will extend into other lifesaving and life-preserving therapeutic categories.

Andy Lane, Commercial Director at The Native Antigen Company, UK

I remember when reports of a novel coronavirus first began to emerge in late December. Somebody mentioned it at the weekly product development meeting – more as a curiosity than anything else.

However, it soon became apparent that the new coronavirus was something serious for us to contend with. Within days, the outbreak in Wuhan ballooned to hundreds of cases, turning heads in academia and industry, alike. Wild speculation followed. Were we on the verge of a global pandemic? Was this the next Disease X?

As cases continued to mount, there was little we could do but sit and wait. R&D were desperate to start their projects, but with no gene sequence, there was nothing to work with. Then, in early January one of our scientists stumbled across a draft genome on a virology blog. From there, it was all systems go. R&D set to work designing the plasmids, transfecting the cell lines and exactly one month since the genome was published, we released S1 and S2 subunits of the SARS-CoV-2 Spike protein. 

For me, it’s a strange feeling as I drive through the sleepy Oxfordshire countryside in the morning. Lockdown has made it feel like the world is on pause. Yet, I step in the lab and it’s never been busier. The team remains hard at work and we are now scaling antigen manufacturing capabilities to support more researchers in developing diagnostics and vaccines against COVID-19, which will be vital in stemming the spread of this disease.

Adrian Wildfire, Scientific Director at SGS

The COVID-19 crisis is prompting the vaccine industry to find new ways of accelerating research and development, and we’re also seeing regulators taking unprecedented steps to help us. I was interested to note recent guidelines from a virtual workshop on COVID-19, convened by the FDA and EMA, involving global representatives. Although the meeting acknowledged the theoretical risks of vaccine-induced disease enhancement, which would need to be addressed during first-in-human trials, they also agreed upon a number of pathways to licensure and gave practical suggestions, including a decreased emphasis on efficacy and safety studies for proven platforms: “It is not required to demonstrate the efficacy of the SARS-CoV-2 vaccine candidate in animal challenge models prior to proceeding to FIH clinical trials” (

The regulators are also looking at how they can reduce legislative burden and actively progress drug and vaccine candidates into the clinic. The FDA has set up the Coronavirus Treatment Acceleration Program, with the stated aim to: “use(s) every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful” ( Additionally, the EMA has waived fees for scientific advice for COVID-19 related drugs and vaccines, and is ready to review any applications for marketing authorization within the “shortest possible timelines.”

The industry and its regulators are proactively working to identify and progress novel solutions, but we need to ensure that this focus is maintained – even following the end of the current COVID-19 pandemic – because coronaviruses will not be the last threat to mankind. Overpopulation, globalization, and unrestricted international travel will mean that future pandemics could see a faster spread with much higher mortality, including children. In my view, I think we should listen to CEPI’s advice: “[...] we should continue developing the most promising (vaccine) candidates to a point at which they can be stockpiled and ready for trials and emergency authorization should an outbreak recur. A global financing system that supports end-to-end development [...] will be a critical component of future pandemic preparedness.”


Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Authors
Mike Grippo

Senior Vice President, Strategy & Corporate Development at Catalent Pharma Solutions

Mike Grippo oversees the strategy and corporate development functions of the company, as well as its scientific team.


Mr. Grippo joined Catalent as Vice President of Corporate Development in 2016, and prior this was Vice President of Corporate Development for CR Bard. Earlier in his career he also held positions with Hill-Rom Holdings, SG Cowen and UBS Securities. Mr. Grippo holds a bachelor’s degree from Princeton University and earned an MBA in Finance from New York University.

Andy Lane

Andy Lane is the Commercial Director at The Native Antigen Company.

Andy studied pathobiology at the University of Reading and completed a PhD in antibody immunotherapy at the University of Southampton. He then joined the NHS and led a monoclonal antibody research group working in leukemia and lymphoma diagnostics. Andy subsequently joined a major monoclonal antibody supplier to lead their new product development. More recently, he was executive director at bioconjugation specialists Innova Biosciences before joining The Native Antigen Company in 2016.

Adrian Wildfire

Adrian Wildfire is Project Director of the SGS Clinical Research Human Challenge Unit.

Adrian Wildfire has worked as an infectious disease specialist for over 30 years, having trained and worked within the fields of bacteriology, virology, parasitology and mycology after obtaining his Fellowship in Medical Microbiology in 1990, and a Masters in Parasitology in 1998. He has specialised in Human Challenge Models for nearly 10 years and is currently leading a multidisciplinary team manufacturing challenge agents for use in clinical trials. He is the author of numerous published papers and articles relating to HIV, ethics and viral challenge amongst others.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine